U.S. market Closed. Opens in 2 hours

GDTC | CytoMed Therapeutics Limited Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue384.75K363.91K113.84K59.47KN/A
Cost of Revenue2.82K8.72K3.50K4.63KN/A
Gross Profit381.92K355.19K110.34K54.84KN/A
Operating Expenses3.69M1.86M1.73M1.26M612.36K
Selling, General & Admin370.67K596.74K588.70K154.87K40.35K
Research & Development1.20M1.52M1.09M1.04M439.86K
Other Operating ExpensesN/A-262.94K48.86K63.29KN/A
Operating Income-2.91M-1.89M-1.94M-1.26M-606.68K
Other Expenses / Income-219.50K-1.15M-209.39K-573.86K-25.93K
Before Tax Income-3.13M-3.13M-2.07M-1.94M-632.61K
Income Tax Expenses494.001.64K-72.25K112.14KN/A
Net Income-3.13M-3.23M-2.07M-1.94M-632.61K
Interest ExpensesN/A125.17K117.70K105.52KN/A
Basic Shares Outstanding10.63M7.92M6.93M5.90M5.55M
Diluted Shares Outstanding10.63M7.92M6.93M5.90M5.55M
EBITDA-2.62M-1.50M-1.61M-963.72K-474.68K
EBITDA Margin-682.22%-410.85%-1,412.07%-1,620.57%0.00%
EBIT-3.13M-3.10M-2.03M-1.72M-632.61K
EBIT Margin-813.86%-852.17%-1,782.39%-2,900.03%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙